Profile
Mr. George A.
Xixis is a Member at Boston Harbor Angels, Inc.
Prior to joining Boston Harbor Angels, Inc., Mr. Xixis was employed as Counsel by CuraGen Corp., Vice President-Business Development by AMDeC Foundation, Inc. and Associate by Kaye Scholer and Fish & Neave.
Mr. Xixis received his BS in Biology from the Massachusetts Institute of Technology, MA in Psychology from New York University and JD in Law from Brooklyn Law School.
Former positions of George A. Xixis
| Companies | Position | End |
|---|---|---|
| AMDeC Foundation, Inc. | Corporate Officer/Principal | 29/01/2003 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Corporate Officer/Principal | - |
Boston Harbor Angels, Inc.
 Boston Harbor Angels, Inc. Investment ManagersFinance Boston Harbor Angels Inc (Boston Harbor Angels) is a venture capital firm founded by Michael Williams in 2004. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | - |
Training of George A. Xixis
| Massachusetts Institute of Technology | Undergraduate Degree |
| New York University | Graduate Degree |
| Brooklyn Law School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Boston Harbor Angels, Inc.
Boston Harbor Angels, Inc. Investment ManagersFinance Boston Harbor Angels Inc (Boston Harbor Angels) is a venture capital firm founded by Michael Williams in 2004. The firm is headquartered in Boston, Massachusetts. | Finance |
| AMDeC Foundation, Inc. | |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
- Stock Market
- Insiders
- George A. Xixis
